Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

mentById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >LGND). It is being developed by GlaxoSmithKline. Eltrombopag is an investigational compound that has not received regulatory approval in any market for any indication at this time.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Note to Editors

PROMACTA(R) is a registered trademark of GlaxoSmithKline group of companies and is the proposed trade name in the United States.

To access the latest GSK news, visit http://us.gsk.com/

Inquiries:

US Media inquiries: Jeff McLaughlin 1 919 483 2839

Mary Anne Rhyne 1 919 483 2839

Nancy Pekarek 1 215 751 7709

US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002

Tom Curry 1 215 751 5419

References:

(1) US Food and Drug Administration. The Orphan Drug act (as amended). Accessed May 2008.
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 General Networks ... MarkLogic Corporation. The alliance ensures joint customers will ... and General Networks’ expertise in building enterprise content ... MarkLogic will help customers integrate, manage and operationalize ... business processes. , “Our customers are seeking tools ...
(Date:5/26/2015)... Foot and Ankle Specialists of ... Leone (Pasadena and Baltimore Divisions) was recently presented ... Medical Association (MPMA) President from 2013 to 2015 at ... Doctorate in Podiatric Medicine from Temple University in 1999 ... in Voorhees, New Jersey. Dr. Leone is an ...
(Date:5/26/2015)... Virginia (PRWEB) May 26, 2015 U.S. ... devices in the United States are extensive and can ... consulting firm that helps medical device companies comply with ... help medical device companies navigate FDA requirements. , ... in the United States can be a lengthy process ...
(Date:5/26/2015)... GA (PRWEB) May 26, 2015 The ... Associates are at it again, helping local rescue pets ... 2015. Local dentists, Kirk Kimmerling DDS, Suzanna Aguilera ... veterinarian, Julian Peckich DVM donating 100% of proceeds from ... to fill the parking lot to help save unwanted, ...
(Date:5/25/2015)... TX (PRWEB) May 26, 2015 ... 2015” provides comprehensive information on the therapeutic development ... by identifying new targets and MOAs to produce ... 2015 pipeline review of Liver Failure with 22 ... 65 pages is available at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html ...
Breaking Medicine News(10 mins):Health News:General Networks Corporation Announces Alliance with MarkLogic 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives MPMA Service Award 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4Health News:"Rescue Animal Cookout" Announced at Verde Pointe Professional Park on June 25, 2015 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... researcher says he completed the task for $50,000 , ... he was able to sequence his entire genome for less ... "This is the first demonstration that you don,t need a ... professor of engineering at Stanford University, said in a news ...
... lead to protein deficiency , , TUESDAY, Aug. 11 ... muscular dystrophy has been identified by Japanese researchers. , ... with muscular dystrophy and degeneration of their fat tissue, ... but they did not have mutations in the caveolin-3 ...
... ... and medical equipment will now be widely available to healthcare professionals online via Target.com. ... faces during doctors, visits so they will be more relaxed and cooperative, improving productivity ... ...
... , KENILWORTH, N.J., Aug. 11 Schering-Plough Corporation (NYSE: ... antihistamine eye drop strong enough to control itchy eyes all day or ... sold, CLARITIN Eye works in minutes to relieve the itch of allergy ... , To view the Multimedia News Release, go to: ...
... Conn., Aug. 11 VION PHARMACEUTICALS, INC. (OTC ... periods ending June 30, 2009. , , For the ... million, or $0.83 per share compared with a net loss of $7.9 ... common shares outstanding for the three months ended June 30, 2009 and ...
... , , , , ... Fort Worth personal injury attorney John David Hart has filed ... Puerto Rico, Inc., Medtronic USA, Inc. and Medtronic Puerto Rico Operations ... risk of lead fractures which could result in serious injury or ...
Cached Medicine News:Health News:Genome Sequencing Gets More Affordable 2Health News:PediaPals to Market Pediatric Exam Tables and Medical Equipment on Target.com 2Health News:PediaPals to Market Pediatric Exam Tables and Medical Equipment on Target.com 3Health News:Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours 2Health News:Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours 3Health News:Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results 2Health News:Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results 3Health News:Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results 4Health News:Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results 5Health News:Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results 6Health News:Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches 2
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, ... awarded CSL Behring its 2015 Corporate Leadership Award ... advancing science and improving the care of the bleeding disorders ... CEO and Managing Director, CSL Limited, during the NHF Annual ... on May 21. "The National Hemophilia Foundation is ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. (NYSE ... embolic protection systems ("EPS"), today announced that its CGuard TM ... by principle investigator Prof. Piotr Musialek , at the ... Paris, France . PARADIGM, an investigator-initiated ... cutaneous c A roti D revascularization I n ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Cardiac Science Corporation (Nasdaq: CSCX ) and ... announced they have entered into a definitive merger agreement under ... outstanding shares of Cardiac Science common stock for $2.30 USD ... the closing price of Cardiac Science common stock of $2.10 ...
... Oct. 19 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Opto Circuits to Acquire Cardiac Science 2Opto Circuits to Acquire Cardiac Science 3Opto Circuits to Acquire Cardiac Science 4Opto Circuits to Acquire Cardiac Science 5Opto Circuits to Acquire Cardiac Science 6Opto Circuits to Acquire Cardiac Science 7Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 2Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 3Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 4Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 5Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 6Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 7Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 8Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 9Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 10Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 11Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 12Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 13Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 14
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
Fiberoptic lightweight coaxial rotary headlight with variable spot....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
... It is powerful, ... very comfortable, soft, durable ... cushion pad, covered by ... wrap. Flexible headband easily ...
Medicine Products: